Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Lupin is the 6th largest company in the Indian Pharmaceutical Market
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Cellutions BioStorage is a comprehensive biomaterial storage and logistics company with a vision to leverage advanced technologies to serve biopharmaceutical companies
She joins Enveda from Gilead Sciences
Subscribe To Our Newsletter & Stay Updated